To our knowledge, no studies have evaluated the efficacy of more potent and bioavailable small molecule MDM2 inhibitors currently in clinical trials, such as navtemadlin (previously known as AMG 232), in hypoxic cancer cells. Here, MDM2 is linked to cancer.